Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988367 | 0.79 | RORC (0.40) | ALDH1A1 | |
| SCHEMBL3994459 | 0.76 | PCSK9 (0.51) | — | |
| SCHEMBL28242027 | 0.75 | KMO (0.40) | KMO | |
| SCHEMBL3440833 | 0.73 | CES2 (0.74) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL10172506 | 0.72 | CPS1 (0.47) | HPGDALDH1A1RAB9A | |
| SCHEMBL7474064 | 0.72 | NAPRT (0.49) | CES2CES1BCHEALDH1A1ALOX15 | |
| SCHEMBL3655141 | 0.71 | KMT2A (0.50) | KMOHPGDALDH1A1L3MBTL1RAB9A | |
| SCHEMBL3979300 | 0.69 | CDK2 (0.36) | ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5613020 | 0.68 | CES2 (0.65) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL3990312 | 0.68 | TDO2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386558-B1 | CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2014-10-01 | — | — | EP | disclosed |
| EP-2386558-B1 | CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2014-10-01 | — | — | EP | disclosed |
| US-8450327-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8450327-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8450327-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2205599-B1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-06-06 | — | — | EP | disclosed |
| EP-2386558-A1 | CGRP antagonists | Boehringer Ingelheim International GmbH (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20110253722-A1 | METHOD AND SYSTEM FOR WATERPROOFING A MOBILE DEVICE | TOMORROW'S INNOVATIONS (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110172218-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172218-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172218-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-2205599-A1 | CGRP ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050234-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172218-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | CES2 2998/4885CES1 2285/4885BCHE 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.